The pharmacogenetics of the response to warfarin in Chinese

British Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2012, Pages 340-347

  Lam, May P S ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Algorithm; Chinese; CYP2C9 gene; VKORC1 gene; Warfarin

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME; CYTOCHROME P450 2C9; CYTOCHROME P450 CYP4F2; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; GAMMA GLUTAMYL CARBOXYLASE; HYDROLASE; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ARTICLE; ASIAN; CAUCASIAN; CHINA; CHINESE; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNICITY; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENE STRUCTURE; GENETIC VARIABILITY; GENOTYPE; HEMATURIA; HEMOPTYSIS; HEREDITY; HONG KONG; HUMAN; INDIA; INDONESIA; LOW DRUG DOSE; MALAYSIA; PHARMACOGENETICS; PHILIPPINES; PRIORITY JOURNAL; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; THAILAND; VIET NAM;

EID: 84857018427     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04097.x     Document Type: Article

References (51)

1. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
2. Lal S, Rao Jada S, Xiang X, Lim W-T, Lee EJD, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet 2006; 45: 1189-200.
3. Lindh J, Holm L, Andersson M, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65: 365-75.
4. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res 2010; 125: e159-e66.
5. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
6. Yu HCM, Chan TYK, Critchley JAJH, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996; 89: 127-36.
7. You JHS, Chan FWH, Wong RSM, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-7.
8. Gladding P, Mackay J, Zeng I, Stewart R, Prabkahar R, Webster M, White H. A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. Personalized Medicine 2010; 7: 319-25.
9. Gage BF. Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program 2006; 467-73.
10. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 Is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009; 75: 1337-46.
11. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-12.
12. Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A, Altman RB. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010; 20: 407-13.
13. Carlquist J, Horne B, Mower C, Park J, Huntinghouse J, McKinney J, Muhlestein J, Anderson J. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis 2010; 30: 358-64.
14. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2010; 70: 234-40.
15. Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab Pharmacokinet 2011; 26: 130-6.
16. Lee MM, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009; 10: 1905-13.
17. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7: 99-111.
18. Gu Q, Kong Y, Schneede J, Xiao YB, Chen L, Zhong QJ, Wang XF, Hao J, Chen BC, Chen JJ. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur J Clin Pharmacol 2010; 66: 1217-27.
19. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, Tai S. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008; 396: 76-9.
20. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 365-72.
21. Chan SL, Thalamuthu A, Goh BC, Chia KS, Chuah B, Wong A, Lee SC. Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. Pharmacogenet Genomics 2011; 21: 35-41.
22. Presnell S, Stafford D. The vitamin K-dependent carboxylase. Thromb Haemost 2002; 87: 937-46.
23. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-70.
24. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 2005; 106: 3673-4.
25. King C, Deych E, Milligan P, Eby C, Lenzini P, Grice G, Porche-Sorbet R, Ridker P, Gage B. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104: 750-4.
26. Huang S-W, Xiang XD-K, Huang L, Chen B-L, An B-Q, Li G-F, Luo Z-Y. Influence of GGCX genotype on warfarin dose requirements in Chinese patients. Thromb Res 2011; 127: 131-4.
27. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008; 47: 565-94.
28. Kohnke H, Sörlin K, Granath G, Wadelius M. Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 2005; 61: 381-8.
29. Lal S, Sandanaraj E, Jada SR, Kong M-C, Lee L-H, Goh B-C, Lee S-C, Chowbay B. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 2008; 65: 260-4.
30. Chern HD, Ueng TH, Fu YP, Cheng CW. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 2006; 367: 108-13.
31. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009; 10: 1243-55.
32. Lee MTM, Chen CH, Chuang HP, Lu LS, Chou CH, Chen YT, Liu CY, Wen MS, Lu JJ, Chang CF, Wu JY, Chen YT. VKORC1 haplotypes in five East-Asian populations and Indians. Pharmacogenomics 2009; 10: 1609-16.
33. Gan G, Phipps M, Lee M, Lu L, Subramaniam R, Bee P, Chang S. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann Hematol 2011; 90: 635-41.
34. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010; 55: 582-89.
35. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
36. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-92.
37. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN. A pharmacometric model describing the relationship between warfarin dose and INR response With respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727-34.
38. Ngow H, Wan Khairina W, Teh L, Lee W, Harun R, Ismail R, Salleh M. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J 2009; 50: 490-3.
39. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
40. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
41. Larramendy-Gozalo C, Yang J, Verstuyft C, Bodin L, Dubert L, Zhang Y, Xu C, Fan L, Jaillon P, Becquemont L. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006; 98: 611-3.
42. You J, Wong R, Waye M, Mu Y, Lim C, Choi K-c CG. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2011; 31: 113-8.
43. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-91.
44. Yuan HY, Chen JJ, Lee MTM, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
45. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19: 226-34.
46. Sandanaraj E, Lai S, Cheung Y, Xiang X, Kong M, Lee L, Ooi L, Chowbay B. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metab Pharmacokinet 2009; 24: 365-75.
47. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006; 80: 346-55.
48. Wen MS, Lee MTM, Chen JJ, Chuang HP, Lu LS, Chen CH, Lee TH, Kuo CT, Sun FM, Chang YJ, Kuan PL, Chen YF, Charng MJ, Ray CY, Wu JY, Chen YT. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008; 84: 83-9.
49. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008; 9: 169-78.
50. Yang J, Huang C, Shen Z, Miao L. Contribution of 1173C>T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. Int J Clin Pharmacol Ther 2011; 49: 23-9.
51. Chan SL, Suo C, Lee SC, Goh BC, Chia KS, Teo YY. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J [Epub ahead of print] 2011. doi: 10.1038/tpj.2011.7.